Skip to main content
SpringerLink
Log in

Bepridil

A Review of its Pharmacological Properties and Therapeutic Use in Stable Angina Pectoris

  • Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Synopsis

Bepridil is a calcium antagonist with direct negative chronotropic, dromotropic, inotropic and vasodilatory actions which reduces myocardial oxygen consumption and increases coronary blood flow, leading to a significant anti-ischaemic and antianginal effect in the absence of reflex tachycardia. In contrast to other calcium channel blockers, bepridil produces only modest peripheral vasodilatation and displays weak antihypertensive activity. Its plasma elimination half-life of 1 to 2 days permits once daily administration.

Results of short term clinical trials have shown bepridil to be of comparable efficacy to nifedipine, verapamil, diltiazem, propranolol and nadolol in decreasing the frequency of anginal attacks and consumption of nitroglycerin (glyceryl trinitrate) in patients with stable angina. Bepridil is more effective than nifedipine in improving exercise performance in patients with stable angina. Although bepridil proved superior to diltiazem in improving exercise performance in patients refractory to diltiazem, further studies are required to confirm the efficacy of bepridil in patients refractory to, or intolerant of, other antianginal agents.

Bepridil in therapeutic doses is well tolerated, and appears to have a similar adverse effect profile to the established calcium antagonists. However, rate-dependent prolongation of the QTc interval and development of torsade de pointes have been associated with the use of bepridil. Therefore, bepridil is contraindicated in patients with hypokalaemia, those receiving other drugs that may prolong the QT interval, and those with congenital QT interval prolongation. Future clinical research will help to further define the position of bepridil as an antianginal treatment relative to the traditional calcium antagonists; in the interim, bepridil is indicated for the treatment of patients with angina refractory to or intolerant of other agents.

Pharmacodynamic Properties

Bepridil blocks slow calcium channels in the myocardium and vascular smooth muscle, and fast sodium channels in cardiac tissues. In contrast to other calcium channel blockers, bepridil inhibits both receptor-operated and voltage-operated calcium channels in vascular smooth muscle. Bepridil also inhibits the potassium current and the intracellular calcium/calmodulin complex. Studies in humans have shown that the resultant effects are a dose proportional reduction in heart rate, a rate-dependent prolongation of the QTc interval, an increase in atrial and ventricular refractoriness, and coronary vasodilatation. The diminished myocardial oxygen consumption and increased coronary blood flow (47% in patients receiving intravenous bepridil 4 mg/kg) result in attenuation of anginal symptoms. There is evidence that bepridil permits an increase in workload while preserving left ventricular function; patients with ischaemic heart disease have experienced a slight exercise-related increase in ejection fraction (from 60 to 62%) during bepridil therapy compared to a reduction (from 60 to 55%) with placebo.

The negative chronotropic effect of bepridil is thought to be due at least in part to a direct effect of the drug on the sinus node. Experiments in animals and humans have shown that intravenous bepridil increases coronary blood flow, decreases heart rate, and increases Wenckebach periodicity by 16 to 20% in the anterograde and 23 to 26% in the retrograde direction in humans. Bepridil also prolongs the functional and effective refractory periods of atrial myocardium, atrio-ventricular node, His-Purkinje system and right ventricular myocardium.

Preliminary animal findings suggest that bepridil may protect against calcium overload during myocardial ischaemia and reperfusion.

Pharmacokinetic Properties

Although bepridil is virtually completely absorbed from the gastrointestinal tract following oral administration, first pass hepatic metabolism reduces its systemic bioavailability to approximately 60%. Peak steady-state plasma bepridil concentrations of 1.0 to 1.5 mg/L (Cmax) occurred in healthy volunteers receiving oral bepridil 300 mg/day. Cmax was observed after approximately 2 hours (tmax), and tmax was increased about 2-fold when bepridil was administered after food, but the extent of absorption (≈ 100%) was unaltered. Bepridil has a distribution half-life of approximately 2 hours and an apparent volume of distribution of 8 L/kg. Bepridil undergoes extensive hepatic biotransformation, with <0.1% of the parent drug being recovered unchanged in the urine and about 1% in the faeces. At least 17 metabolites of bepridil have been identified, only 1 of which retains pharmacological activity. These metabolites are primarily excreted via the urine. The elimination half-life in healthy volunteers ranges from 1 to 2 days following a single oral 300mg dose, and during maintenance therapy.

In elderly patients, Cmax was increased 3-fold and the elimination half-life increased more than 2-fold compared with values estimated for younger volunteers. Reduced bepridil clearance has been observed in patients with renal or hepatic impairment, and in patients with coronary artery disease.

Therapeutic Efficacy

Bepridil in doses of 200 to 400 mg/day is beneficial in alleviating symptoms of stable angina. Bepridil 200 to 450 mg/day significantly increased total exercise duration, time to onset of angina and time to 1mm ST-segment depression by up to 41, 57 and 43%, respectively, compared with placebo. Furthermore, anginal attack frequency and nitroglycerin (glyceryl trinitrate) consumption decreased by approximately 40 to 80%, and these benefits were maintained for up to 2 years on long term therapy. Results from a limited number of comparative studies indicate that bepridil 400 mg/day is at least as effective as propranolol 220 mg/day, and the combination of bepridil 200 to 400 mg/day plus propranolol 160 to 240 mg/day has proved effective in patients inadequately controlled with propranolol alone. Bepridil has proved as effective as nifedipine, verapamil, nadolol and diltiazem in controlling anginal symptoms, and superior to nifedipine in improving exercise performance. While bepridil has been shown to be more effective than diltiazem in improving exercise performance in patients with stable angina refactory to diltiazem, further comparative trials are required to confirm the efficacy of bepridil in the treatment of patients refractory to other antianginal agents.

Tolerability

Bepridil in doses of up to 400 mg/day has been well tolerated in clinical trials, the most frequently reported adverse effects being gastrointestinal symptoms such as dyspepsia, nausea and diarrhoea, and neurological symptoms such as dizziness and tremor.

Numerous cases of torsade de pointes have been documented since the introduction of bepridil into clinical practice. Proarrhythmic risk factors include bradycardia, excessive prolongation of the QT interval, low serum potassium levels and, possibly, accumulation of bepridil. Since the introduction of more detailed guidelines regarding ECG and serum potassium monitoring, and the use of co-medications, the incidence of bepridil-induced torsade de pointes has declined to about 0.01%. Bepridil has been used safely in conjunction with both short- and long-acting nitrates, anticoagulants, aspirin, oral hypoglycaemics or β-blockers in patients with relatively well-preserved cardiac function. The safety of bepridil plus β-blockers in patients with impaired ventricular function or cardiac conduction abnormalities remains to be fully assessed.

Dosage and Administration

The recommended starting dose and usual maintenance dose of orally administered bepridil is 300 mg/day, and the maximum permitted dose is 400 mg/day. In elderly patients and those with hepatic or renal impairment, the recommended starting dose and usual maintenance dose is 200 mg/day, while the maximum permitted dose in these patients is 300 mg/day. The long elimination half-life of bepridil allows for once daily dosing. Due to their increased risk of ventricular arrhythmias with the drug, elderly patients and those with renal or hepatic impairment should be monitored frequently and dosage adjustments should be performed as necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alpert JS, Coumel P, Greeff K, Krikler DM, Remme WJ, et al. Bepridil: a review of its pharmacology and clinical efficacy as an anti-anginal agent with anti-arrhythmic properties. Pharmatherapeutica 4: 195–222, 1985

    PubMed  CAS  Google Scholar 

  • Alpert JS, Gore JM, DiBianco R, Katz RJ, Spann J, et al. Anti-anginal efficacy of bepridil, a long acting calcium channel blocker: results of a 10 week, multicenter, placebo controlled study. Revue de Médecine 28: 1307–1311, 1983

    Google Scholar 

  • Amor M, Hocquard C, Karcher G, Verdaguer M, et al. Amélioration sous bépridil intraveineux de la fonction ventriculaire gauche a l’effort. Revue de Médecine 28: 1293–1303, 1983

    Google Scholar 

  • Apoil E, Schönbaum E. The clinical application of bepridil. Progress in Pharmacology 5/4: 1–13, 1985

    Google Scholar 

  • Beaughard M, Ferner M, Labrid C, Lamar JC, Leboeuf J, et al. Studies on the bradycardia induced by bepridil. British Journal of Pharmacology 75: 293–300, 1982

    PubMed  CAS  Google Scholar 

  • Beaughard M, Michelin MT, Tisne-Versailles J, Lamar JC. Comparative effects of bepridil, diltiazem, nifedipine and verapamil on haemodynamic parameters and myocardial oxygen consumption in anaesthetized dogs. Archives Internationales de Pharmacodynamie et de Thérapie 284: 276–296, 1986

    PubMed  CAS  Google Scholar 

  • Benet LZ. Pharmacokinetics and metabolism of bepridil. American Journal of Cardiology 55 (Suppl.C): 8C–13C, 1985

    PubMed  CAS  Google Scholar 

  • Berger F, Borchard U, Hafner D. Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres. Naunyn Schmeideberg’s Archives of Pharmacology 339: 638–646, 1989

    CAS  Google Scholar 

  • Boddeke EWGM, Wilffert B, Heynis JB, Hugtenburg JG, Jap WTJ, et al. The anti-ischaemic activity of the novel compound, CERM 11956, compared with that of bepridil and nifedipine in isolated guinea-pig hearts. European Journal of Pharmacology 149: 195–203, 1988

    PubMed  CAS  Google Scholar 

  • Boucher M, Duchêne-Marullaz D. Comparative effects of amiodarone, perhexiline and bepridil on the cardiac rhythms of the unanesthetized dog in chronic heart block. Archives Internationales de Pharmacodynamie et de Thérapie 233: 65–75, 1978

    PubMed  CAS  Google Scholar 

  • Braunwald E. Mechanism of action of calcium-channel-blocking agents. New England Journal of Medicine 307: 1618–1627, 1982

    PubMed  CAS  Google Scholar 

  • Buckley JP, Steenberg ML, Landhyala BS. Chronic cardiovascular effects of bepridil in anaesthetized and conscious dogs. Drug Development Research 3: 535–544, 1983

    CAS  Google Scholar 

  • Buckley MMT, Grant SM, Goa KL, McTavish D, Sorkin EM. Diltiazem. A reappraisal of its pharmacological properties and therapeutic use. Drugs 39: 757–806, 1990

    PubMed  CAS  Google Scholar 

  • Constantin M, Bromont C, Fickat R, Massingham R. Studies on the activity of bepridil as a scavenger of free radicals. Biochemical Pharmacology 40: 1615–1622, 1990

    PubMed  CAS  Google Scholar 

  • Cosnier D. Duchêne-Marullaz P. Rispat G, Streichenberger G. Cardiovascular pharmacology of bepridil (1[3 isobutoxy 2 (benzylphenyl) amino] propyl pyrrolidine hydrochloride), a new potential anti-anginal compound. Archives Internationales de Pharmacodynamie et de Thérapie 225: 133–151, 1977

    PubMed  CAS  Google Scholar 

  • Coumel P. Safety of bepridil: from review of the European data. American Journal of Cardiology 69 (Suppl.D): 75D–78D, 1992

    PubMed  CAS  Google Scholar 

  • Cramb G, Dow JW. Uptake of bepridil into isolated ventricular myocytes. Retention by actin. Biochemical Pharmacology 32: 227–231, 1983

    PubMed  CAS  Google Scholar 

  • Cruz C, Zaoui A, Berson G, Younes A. Protective effects of bepridil on calcium injury of anoxic myocytes isolated from adult rat heart ventricular muscle. Journal of Pharmacology and Experimental Therapeutics 242: 1126–1132, 1987

    PubMed  CAS  Google Scholar 

  • Dangman KH. Effects of bepridil on transmembrane action potentials recorded from isolated canine cardiac tissues. Naunyn Schmeideberg’s Archives of Pharmacology 329: 326–332, 1985

    CAS  Google Scholar 

  • Deedwania P, Carbajal E. Propranolol is better than bepridil for the treatment of ambulatory myocardial ischemia. Abstract Clinical Pharmacology and Therapeutics 47: 170, 1990

    Google Scholar 

  • De Marco T, Deedwania P, Chatterjee K. Systemic and coronary hemodynamic effects of bepridil in patients with depressed left ventricular function. American Journal of Cardiology 69 (Suppl.D): 31D–36D, 1992

    PubMed  Google Scholar 

  • Desiraju RK, Gemzik B, Nayak RK, Esterling DE. Steady-state dose proportionality and pharmacokinetics of bepridil in healthy volunteers. Abstract Clinical Pharmacology and Therapeutics 35: 234, 1984

    Google Scholar 

  • Destors JM, Boissel JP, Philippon AM, Schbath J. Controlled clinical trial of bepridil, propranolol and placebo in the treatment of exercise induced angina pectoris. Fundamentals of Clinical Pharmacology 3: 597–611, 1989

    CAS  Google Scholar 

  • DiBianco R. Bepridil treatment of chronic stable angina: a review of comparative studies versus placebo, nifedipine and diltiazem. American Journal of Cardiology 69 (Suppl.): 56D–62D, 1992

    PubMed  CAS  Google Scholar 

  • DiBianco R, Alpert J, Katz RJ, Spann J, Chesler E, et al. Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled dose-ranging study in 77 patients. American Journal of Cardiology 53: 35–41, 1984

    PubMed  CAS  Google Scholar 

  • DiBianco R, Katz RJ, Chesler E, Alpert JS, Spann JF. Long-term efficacy of bepridil in patients with chronic stable angina pectoris: results of a multicenter, placebo-controlled study of extended bepridil use. American Journal of Cardiology 55 (Suppl.C): 50C–54C, 1985

    PubMed  CAS  Google Scholar 

  • Duchêne-Marullaz P, Kantelip J-P, Trolèse J-F. Effects of bepridil, a new antianginal agent, on ambulatory electrocardiography in human volunteers. Journal of Cardiovascular Pharmacology 5: 506–510, 1983

    PubMed  Google Scholar 

  • El-Saleh SC, Solaro RJ. Calmidazolium, a calmodulin antagonist, stimulates calcium-troponin C and calcium-calmodulin-dependent activation of striated muscle myofilaments. Journal of Biological Chemistry 262: 17240–17246, 1987

    PubMed  CAS  Google Scholar 

  • Fauchier JP, Cosnay P, Rouesnel P, Neel C, Latour F. Traitement des tachycardies ventriculaires du coronarien par bépridil intraveineux et par voie orale. Revue de Médecine 24: 1341–1347, 1983

    Google Scholar 

  • Flaim SF, Ratz PH, Swigart SC, Gleason MM. Bepridil hydrochloride alters potential-dependent and receptor-operated calcium channels in vascular smooth muscle of rabbit aorta. Journal of Pharmacology and Experimental Therapeutics 234: 63–71, 1985

    PubMed  CAS  Google Scholar 

  • Flaim SF, Stranieri MT, Mathiasen IR. Effects of bepridil hydrochloride on cardiocirculatory dynamics, coronary vascular resistance, and cardiac output distribution in normal, conscious rats. Journal of Cardiovascular Pharmacology 11: 363–372, 1988

    PubMed  CAS  Google Scholar 

  • Flammang D, Waynberger M, Jansen FH, Paillet R, Coumel Ph. Electrophysiological profile of bepridil, a new anti-anginal drug with calcium blocking properties. European Heart Journal 4: 647–654, 1983

    Google Scholar 

  • Frishman WH. Comparative efficacy and concomitant use of bepridil and beta blockers in the management of angina pectoris. American Journal of Cardiology 69 (Suppl.D): 50D–55D, 1992

    PubMed  CAS  Google Scholar 

  • Frishman WH, Charlap S, Farnham DJ, Sawin HS, Michelson EL, et al. Combination propranolol and bepridil therapy in stable angina pectoris. American Journal of Cardiology 55 (Suppl.C): 43C–49C, 1985

    PubMed  CAS  Google Scholar 

  • Funck-Brentano C, Coudray P, Planellas J, Motté G, Jaillon P. Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris. American Journal of Cardiology 66: 812–817, 1990

    PubMed  CAS  Google Scholar 

  • Gill A, Flaim SF, Damiano BP, Sit SP, Brannan MD. Pharmacology of bepridil. American Journal of Pharmacology 69 (Suppl.D): 11D–16D, 1992

    CAS  Google Scholar 

  • Gleason MM, Gill A. Brannan MD, Flaim SF. Effects of bepridil hydrochloride on calcium-induced responses in guinea pig Langendorff heart. Pharmacology 33: 76–85, 1986

    PubMed  CAS  Google Scholar 

  • Guo Z-G, Tang X-L. Norepinephrine release during ischemia/reperfusion and the effects of bepridil and propranolol on myocardial injury in isolated working guinea pig hearts European Journal of Pharmacology 183: 603, 1990

    Google Scholar 

  • Hakamäki T, Apoil E, Arstila M, Timmer CJ, Lehtonen A. Bepridil in the elderly. A pharmacokinetic and clinical monitoring study. Current Therapeutic Research 44: 752–758, 1988

    Google Scholar 

  • Hanaki Y, Sugiyama S, Hieda N, Taki K, Ozawa T. Cardioprotective effect of bepridil on ischemic myocardial damages in dogs. Archives Internationales de Pharmacodynamie et de Thérapie 299 (Suppl.3): 221–231, 1989

    PubMed  CAS  Google Scholar 

  • Hasegawa GR. Nicardipine, nitrendipine, and bepridil: new calcium antagonists for cardiovascular disorders. Clinical Pharmacy 7: 97–108, 1988

    PubMed  CAS  Google Scholar 

  • Hill JA, O’Brien JT, Alpert JS, Gore JM. Zusman RM, et al. Effect of bepridil in patients with chronic stable angina: results of a multicenter trial. Circulation 71: 98–103, 1985

    PubMed  CAS  Google Scholar 

  • Hill JA, O’Brien JT, Scott E, Conti CR, Pepine CJ. Effects of bepridil on exercise tolerance in chronic stable angina: a double-blind, randomized, placebo-controlled, crossover trial. American Journal of Cardiology 53: 679–683, 1984

    PubMed  CAS  Google Scholar 

  • Hill JA, Pepine CJ. Effects of bepridil on the resting electrocardiogram. International Journal of Cardiology 6: 319–323, 1984

    PubMed  CAS  Google Scholar 

  • Holland ML, Ng KT. Automated capillary gas Chromatographic assay using nitrogen-phosphorus ionization detection for the determination of bepridil in human plasma. Journal of Chromatography 374: 87–93, 1986

    PubMed  CAS  Google Scholar 

  • Hugtenburg JG, Mathy M-J, Veldsema-Currie RD, Boddeke HWGM, Beckeringh JJ, et al. A comparison of the cardioprotective effects of calcium antagonists from different classes upon ischaemic damage in the guinea-pig working heart. Naunyn Schmiedeberg’s Archives of Pharmacology 340: 126–134, 1989

    PubMed  CAS  Google Scholar 

  • Huizer T, de Jong JW, Achterberg PW. Protection by bepridil against myocardial ATP metabolism is probably due to negative inotropy. Journal of Cardiovascular Pharmacology 10: 55–61, 1987

    PubMed  CAS  Google Scholar 

  • Itoh H, Tanaka T, Mitani Y, Hidaka H. The binding of the calcium channel blocker, bepridil, to calmodulin. Biochemical Pharmacology 35: 217–220, 1986

    PubMed  CAS  Google Scholar 

  • Jackson CV, Mitsos SE, Simpson PJ, Driscoll EM, Lucchesi BR. Effects of bepridil on regional and global myocardial ischemia/reperfusion-induced injury. Pharmacology 30: 320–332, 1985.

    PubMed  CAS  Google Scholar 

  • Jaillon P, Girard M, Ponsonnaille J. Tolérance électrocardiographique du bépridil (Cordium). La Lettre du Pharmacologue 5: 202–206, 1991

    Google Scholar 

  • Josephson MA, Mody T, Coyle K, Singh BN. Effects on hemodynamics and left ventricular fraction of intravenous bepridil for impaired left ventricular function secondary to coronary artery disease. American Journal of Cardiology 60: 44–49, 1987

    PubMed  CAS  Google Scholar 

  • Jullien JL, Baillon R, Benaim R, Blanc-Pardigan M, Donzeau JP, et al. Étude de l’action du bépridil sur les extrasystoles ventriculaires. Revue de Médecine 24: 1327–1332, 1983

    Google Scholar 

  • Kaczorowski GJ, Slaughter RS, Garcia ML, King VF. Block of cardiac sodium-calcium exchange by mechanism-based inhibitors. Progress in Clinical and Biological Research 252: 261–266, 1988

    PubMed  CAS  Google Scholar 

  • Kane KA, Winslow E. Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil. Journal of Cardiovascular Pharmacology 2: 193–203, 1980

    PubMed  CAS  Google Scholar 

  • Kane KA, Parratt JR, Williams FM. An investigation into the characteristics of reperfusion-induced arrhythmias in the anaesthetised rat and their susceptibility to antiarrhythmic agents. British Journal of Pharmacology 82: 349–357, 1984

    PubMed  CAS  Google Scholar 

  • Kantelip JP, Alatienne M, Talmant JM, Ghyselinck N, Duchêne-Marullaz P. Comparative electrophysiologic effects of bepridil, verapamil and diltiazem in conscious and anaesthetized dogs. Archives Internationales de Pharmacodynamie et de Thérapie 284: 5–18, 1986

    PubMed  CAS  Google Scholar 

  • Kato K, Hosoda S, Hayakawa H, Murayama M, Iinuma H, et al. Clinical evaluation of bepridil (Org 5730) on angina pectoris. Multicenter double-blind study in comparison with nifedipine. Rinsho Hyoka 17: 429–450, 1989

    Google Scholar 

  • Kato R, Singh BN. Effects of bepridil on the electrophysiologic properties of isolated canine and rabbit myocardial fibers American Heart Journal 111: 271, 1986

    PubMed  CAS  Google Scholar 

  • Katz RJ, Thadani U and the Bepridil-Nifedipine Multicenter Group. Bepridil vs nifedipine for treatment of chronic stable angina. Abstract Journal of the American College of Cardiology 7: 231A, 1986

    Google Scholar 

  • Kirchhof CJHJ, Bonke FIM, Allessie MA, Huijberts MSP. Effects of bepridil on conduction properties of the isolated rabbit sinus node and atrial myocardium. Journal of Cardiovascular Pharmacology 13: 131–137, 1989

    PubMed  CAS  Google Scholar 

  • Kotake H, Igawa O, Miyamoto J, Hasegawa J, Kosaka T, et al. Effect of bepridil on membrane current of rabbit sinoatrial node cells. Arzneimittel-Forschung 37: 424–427, 1987

    PubMed  CAS  Google Scholar 

  • Labrid C, Grosset A, Dureng G, Mironneau J, Duchêne-Marullaz P. Some membrane interactions with bepridil, a new anti-anginal agent. Journal of Pharmacology and Experimental Therapeutics 211: 546–554, 1979

    PubMed  CAS  Google Scholar 

  • Lebouef J, Baissat J, Massingham R. Protective effect of bepridil against veratrine-induced contracture in rat atria. European Journal of Pharmacology 216: 183–189, 1992

    Google Scholar 

  • Leboeuf J, Lamar JC, Massingham R, Ponsonnaille J. Electrophysiological effects of bepridil and its quaternary derivative CERM 11888 in closed chest anaesthetized dogs: a comparison with verapamil and diltiazem. British Journal of Pharmacology 98: 1351–1359, 1989

    PubMed  CAS  Google Scholar 

  • Leclercq JF, Kural S, Valère P. Bépridil et torsades de pointes. Archives des Maladies du Coeur et des Vaisseaux 76: 341–348, 1983

    PubMed  CAS  Google Scholar 

  • Lecocq B, Lecocq V, Prost P-L, Fleurot O, Boisson P, et al. Effects of bepridil and CERM 4205 (ORG 30701) on the relation between cardiac cycle length and QT duration in healthy volunteers. American Journal of Cardiology 66: 636–641, 1990

    PubMed  CAS  Google Scholar 

  • Lesko LJ, Benotti JR, Alpert JS, Brady PM, McCue JE, et al. Pharmacokinetics of intravenous bepridil in patients with coronary disease. Journal of Pharmaceutical Sciences 75: 952–954, 1986

    PubMed  CAS  Google Scholar 

  • Levy S. La bépridil dans la réduction et la prèvention des tachycardies ventriculaires (récividantes). Revue de Médecine 24: 1349–1352, 1983

    Google Scholar 

  • Lynch JJ, Rahwan RG, Lucchesi BR. Antifibrillatory actions of bepridil and butyl-MDI, two intracellular calcium antagonists. European Journal of Pharmacology 11: 9–15, 1985

    Google Scholar 

  • Manouvrier J, Sagot M, Caron C, Vaskmann G, Leroy R, et al. Nine cases of torsade de pointes with bepridil administration. American Heart Journal 111: 1005–1007, 1986

    PubMed  CAS  Google Scholar 

  • Marshall RJ. The effects of anti-anginal agents on experimental ischaemia-induced ventricular arrhythmias. Progress in Pharmacology 54: 61–79, 1985

    Google Scholar 

  • Marshall RJ, Muir AW. The beneficial actions of bepridil in acute myocardial infarction in anaesthetized dogs. British Journal of Pharmacology 73: 471–479, 1981

    PubMed  CAS  Google Scholar 

  • Marshall RJ, Winslow E, Lamar JC, Apoil E. Bepridil. New Drugs Annual: Cardiovascular Drugs 2: 157–176, 1984

    CAS  Google Scholar 

  • Massingham R, Van Zwieten PA. Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia. Cardiovascular Drugs and Therapy 3: 731–742, 1989

    PubMed  CAS  Google Scholar 

  • Matlib MA. Action of bepridil, a new calcium channel blocker, on oxidative phosphorylation, oligomycin-sensitive adenosine triphosphatase activity, swelling Ca++ uptake and Na+-in-duced Ca++ release processes of rabbit heart mitochondria in vitro. Journal of Pharmacology and Experimental Therapeutics 33: 376–381, 1985

    Google Scholar 

  • Matteoli S, Trappolini M, Galli V, Federici AR, Borgia MC, et al. Double blind cross-over study with bepridil and verapamil in patients with stable effort angina. Cardiologia 33: 413–418, 1988

    PubMed  CAS  Google Scholar 

  • McTavish D, Sorkin EM. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38: 19–76, 1989

    PubMed  CAS  Google Scholar 

  • Montluc H, Jaillon P, Biour M, Cheymol G. Effets du bépridil sur la fréquence cardiaque et la pression artérielle au repos et à l’effort chez le sujet sain. Étude des relations effets-concentrations plasmatiques. Thérapie 39: 221–229, 1984

    PubMed  CAS  Google Scholar 

  • Nademanee K, Singh BN. Control of cardiac arrhythmias by calcium antagonists. Annals of the New York Academy of Science 522: 536–552, 1988

    CAS  Google Scholar 

  • Nademanee K, Singh BN, Piontek M, Intarachot V, Yale C. Anti-anginal efficacy of bepridil, a novel calcium antagonist: double-blind evaluation by quantitating myocardial ischemia by compact Holter analog technique in chronic stable angina. Abstract Journal of the American College of Cardiology 3: 551, 1984

    Google Scholar 

  • Narahara KA. Hemodynamic effects of bepridil in patients with coronary artery disease. American Journal of Cardiology 69 (Suppl.D): 17D–24D, 1992

    PubMed  CAS  Google Scholar 

  • Narahara KA, Shapiro W, Weliky I, Park J. Evaluation of bepridil, a new antianginal agent: clinical and hemodynamic alterations during the treatment of stable angina pectoris. American Journal of Cardiology 53: 29–34, 1984

    PubMed  CAS  Google Scholar 

  • Narahara KA, Singh BN, Karliner JS, Corday SR, Hossack K. Bepridil hydrochloride compared with placebo in patients with stable angina pectoris. American Journal of Cardiology 69 (Suppl.D): 37D–42D, 1992

    PubMed  CAS  Google Scholar 

  • Nayak RK, Halstenson CE, Opsahl JA, Desiraju RK, Minn FL, et al. Pharmacokinetics of bepridil in haemodialysis patients. Abstract. Clinical Pharmacology and Therapeutics: 238, 1987

  • Ng K-T, Plutte JA, Galante LJ. Determination of bepridil in biological fluids by high-performance liquid chromatography. Journal of Chromatography 309: 125–131, 1984

    PubMed  CAS  Google Scholar 

  • Nielsen HK, Krusell LR, Husted SE, Pluymers RJ. Bepridil versus verapamil in stable angina pectoris — a controlled clinical trial. International Journal of Cardiology 23: 357–364, 1989

    PubMed  CAS  Google Scholar 

  • Nielsen-Kudsk F, Askholt J, Jakobsen P. Bepridil, myocardial accummulation kinetics and dynamic effects in the isolated rabbit heart. Pharmacology and Toxicology 63: 122–128, 1988

    PubMed  CAS  Google Scholar 

  • Ollivier JP, Droniou J. Effets ergométriques de deux inhibiteurs calciques dans l’angor stable: le bépridil et la nifédipine. Mises à jour cardiologiques 11: 557–564, 1982

    Google Scholar 

  • Pang DC, Sperelakis N. Nifedipine, diltiazem, bepridil and verapamil uptakes into cardiac and smooth muscles. European Journal of Pharmacology 87: 199–207, 1983

    PubMed  CAS  Google Scholar 

  • Parker JO, Farrell B. Comparative antianginal effects of bepridil and propranolol in angina pectoris. American Journal of Cardiology 58: 449–452. 1986

    PubMed  CAS  Google Scholar 

  • Pflugfelder PW, Humen DP, O’Brien PA, Purves PD, Jablonsky G, et al. Comparison of bepridil with nadolol for angina pectoris. American Journal of Cardiology 59: 1283–1288, 1987

    PubMed  CAS  Google Scholar 

  • Ponsonnaille J, Citron B, Threil F, Gras H. Étude des effets électrophysiologiques du bépridil utilisé par voie veineuse. Archives des Maladies du Coeur et des Vaisseaux 75: 1415–1423, 1982

    PubMed  CAS  Google Scholar 

  • Prystowsky EN. Effects of bepridil on cardiac electrophysiologic properties. American Journal of Cardiology 69 (Suppl.D): 63D–67D, 1992

    PubMed  CAS  Google Scholar 

  • Puech P, Coumel Ph, Maison-Blanche PM, Coudray Ph. Étude comparative de la tolérance électrocardiographique et clinique à moyen terme du bépridil par rapport au diltiazem chez le coronarien. Annales de Cardiologie d’Angeiologie 39: 437–442. 1990

    CAS  Google Scholar 

  • Rae AP, Beattie JM, Lawrie TDV, Hutton I. Comparative clinical efficacy of bepridil, propranolol and placebo in patients with chronic stable angina. British Journal of Clinical Pharmacology 19: 343–352, 1985

    PubMed  CAS  Google Scholar 

  • Reifart N, Marston W, Zierler MK, Taylor AD, Kaltenbach M, et al. Effects of bepridil on regional myocardial ischemia and comparison with verapamil. American Journal of Cardiology 58: 541–546, 1986

    PubMed  CAS  Google Scholar 

  • Remme WJ, Kruijssen HACM, Krauss XH, van Hoogenhuyze DCA, Storm CJ. Effets hémodynamiques aigus du bépridil administré en IV chez des patients porteurs d’une maladie artérielle coronaire. Revue de Médecine 28: 1281–1288, 1983

    Google Scholar 

  • Remme WJ, Kruyssen DACM, van Hoogenhuyze DCA, Hofman B, Krauss XH, et al. Acute hemodynamic and antiischemic properties of intravenous bepridil in coronary artery disease. American Journal of Cardiology 63: 670–675, 1989

    PubMed  CAS  Google Scholar 

  • Remme WJ, van Hoogenhuyze DCA, Krauss XH, Hofman A, Storm CJ, et al. Dose related coronary and systemic haemodynamic effects of intravenous bepridil in patients with coronary artery disease. European Heart Journal 8: 130–140, 1987

    PubMed  CAS  Google Scholar 

  • Rowland E, McKenna WJ, Krikler DM. Electrophysiologic and antiarrhythmic actions of bepridil. Comparison with verapamil and ajmaline for atrioventricular reentrant tachycardia. American Journal of Cardiology 55: 1513–1519, 1985

    PubMed  CAS  Google Scholar 

  • Scheldt S. The role of calcium blockers in the treatment of chronic stable angina. In Flaim SF & Zelis R (Eds) Calcium blockers: mechanisms of action and clinical applications, pp. 231–244, Urban and Schwarzenberg, Baltimore, 1982

    Google Scholar 

  • Schneider HTh. Therapeutic efficacy of bepriclil in the treatment of stable angina pectoris. Results of a dose-finding study and comparative study with nifedipine. Revue de Médecine 28: 1312–1316, 1983

    Google Scholar 

  • Shapiro W, DiBianco R, Thadani U, for the Bepridil Collaborative Study Group. Comparative efficacy of 200, 300 and 400mg of bepridil for chronic stable angina pectoris. American Journal of Cardiology 55 (Suppl.C): 36C–42C, 1985

    PubMed  CAS  Google Scholar 

  • Sharma MK, Voyles W, Prasad R, Teague SM, Thadani U, et al. Long-term bepridil monotherapy for angina pectoris. American Journal of Cardiology 61: 1210–1213, 1988

    PubMed  CAS  Google Scholar 

  • Shikano K, Kusagawa M, Itoh H, Hidaka H, Protective effects of the calmodulin antagonist bepridil on ischaemia induced in the rat myocardium. Cardiovascular Research 20: 364–368, 1986

    PubMed  CAS  Google Scholar 

  • Singh BN. Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem. American Journal of Cardiology 68: 306–312, 1991

    PubMed  CAS  Google Scholar 

  • Singh BN. Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. American Journal of Cardiology 69 (Suppl.D): 68D–74D, 1992a

    PubMed  CAS  Google Scholar 

  • Singh BN. Bepridil therapy: guidelines for patient selection and monitoring of therapy. American Journal of Cardiology 69 (Suppl.D): 79D–85D, 1992b

    PubMed  CAS  Google Scholar 

  • Singh BN, Nademanee K, Feld G, Piontek M, Schwab M. Comparative electrophysiologic profiles of calcium antagonists with particular reference to bepridil. American Journal of Cardiology 55 (Suppl. C): 14C–19C, 1985

    PubMed  CAS  Google Scholar 

  • Solaro RJ, Bousquet P, Johnson JD. Stimulation of cardiac my-ofilament force, ATPase activity and troponin C. Ca++ binding by bepridil. Journal of Pharmacology and Experimental Therapeutics 238: 502–507, 1986

    PubMed  CAS  Google Scholar 

  • Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 30: 182–274, 1985

    PubMed  CAS  Google Scholar 

  • Tari C, Fournier N, Ducet G, Crevat A, Albengres E, et al. Comparative study of bepridil and nicardipine action on respiration and calcium transport in mitochondria. International Journal of Clinical Pharmacology, Therapy and Toxicology 25: 26–30, 1987

    CAS  Google Scholar 

  • Théroux P, Taeymans Y, Waters DD. Calcium antagonists. Clinical use in the treatment of angina. Drugs 25: 178–195, 1983

    PubMed  Google Scholar 

  • Upward JW, Daly K, Campbell S, Bergman G, Jewitt DE. Electrophysiologic, hemodynamic and metabolic effects of intravenous bepridil hydrochloride American Journal of Cardiology 55: 1589–1595, 1985

    PubMed  CAS  Google Scholar 

  • Valère PE, Belin A, Chentir T, Lehner JP, Guerot CR, et al. Effects électrophysiologiques du bépridil sur le coeur humain. Annales de Cardiologie et d’Angéiologie 31: 409–415, 1982

    PubMed  Google Scholar 

  • van Amsterdam FTM, Punt NC, Haas M, Zaagsma J. Calcium antagonists show two modes of protection in ischemic heart failure. Journal of Pharmacology and Experimental Therapeutics 253: 277–283, 1990a

    PubMed  Google Scholar 

  • van Amsterdam FTM, Punt NC, Haas M, Zaagsma J. Stereoisomers of calcium antagonists distinguish a myocardial and vascular mode of protection against cardiac ischemic injury. Journal of Cardiovascular Pharmacology 15: 198–204, 1990b

    PubMed  Google Scholar 

  • van Amsterdam FTM, Zaagsma J. pH-Dependent effects of bepridil on Ca2+ extrusion across rat heart sarcolemma. Archives Internationales de Pharmacodynamie et de Thérapie 298: 90–95, 1989

    PubMed  Google Scholar 

  • Verdouw PD, Scheffer MG. Cardiovascular actions after intravenous and intracoronary administration of the slow channel blocker bepridil. Arzneimittel-Forschung 34: 21–25, 1984

    PubMed  CAS  Google Scholar 

  • Vogel S, Crampton R, Sperelakis N. Blockade of myocardial slow channels by bepridil (CERM-1978). Journal of Pharmacology and Experimental Therapeutics 210: 378–385, 1979

    PubMed  CAS  Google Scholar 

  • Watts J, Maiorano P, Harwell T. Comparison of the effects of bepridil and diltiazem upon globally ischemic rat hearts. European Journal of Pharmacology 134: 25–33, 1987

    PubMed  CAS  Google Scholar 

  • Wilhelm D, Scheufler E, Peters T. Differential influence of various calcium-modulating compounds on ouabain intoxication in isolated rat left atria Pharmacology 41: 316, 1990

    PubMed  CAS  Google Scholar 

  • Winslow E, Hope F, Marshall RJ. Comparative effects of fast-and slow-ion channel blocking agents on reperfusion-induced arrhythmias in the isolated perfused rat heart. Journal of Cardiovascular Pharmacology 5: 928–936, 1983

    PubMed  CAS  Google Scholar 

  • Winslow E, Wright P, Campbell JK, Marshall RJ. Comparative effects of the isomers of bepridil on isolated coronary and aortic arteries. European Journal of Pharmacology 166: 241–249, 1989

    PubMed  CAS  Google Scholar 

  • Wu WN, Hills JF, Chang SY, Ng KT. Metabolism of bepridil in laboratory animals and humans. Drug Metabolism and Disposition 16: 69–77, 1988

    PubMed  CAS  Google Scholar 

  • Wu WN, Pritchard JF, Ng KT, Hills JF, Uetz JA, et al. Disposition of bepridil in laboratory animals and man. Xenobiotica 22: 153–169, 1992

    PubMed  CAS  Google Scholar 

  • Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calcium and sodium channels. Journal of Pharmacology and Experimental Therapeutics 237: 9–17, 1986

    PubMed  CAS  Google Scholar 

  • Younes A, Fontanarava C, Schneider JM. Effects of bepridil on the Ca-dependent ATPase activity of sarcoplasmic reticulum. Biochemical Pharmacology 30: 2979–2982, 1981

    PubMed  CAS  Google Scholar 

  • Younes A, Schneider J-M. Effects of bepridil on Ca2+ uptake by cardiac mitochondria. Biochemical Pharmacology 33: 1363–1366, 1984

    PubMed  CAS  Google Scholar 

  • Zeller FP, Spinler SA. Bepridil: a new long-acting calcium channel blocking agent. Drug Intelligence and Clinical Pharmacy 21: 487–492, 1987

    PubMed  CAS  Google Scholar 

  • Zusman RM, Christensen D, Higgins J, Boucher CA. Effects of antianginal therapy on left ventricular systolic and diastolic performance: comparison of the response to bepridil, propranolol, and diltiazem. American Journal of Cardiology 69 (Suppl.D): 25D–30D, 1992

    PubMed  CAS  Google Scholar 

  • Zusman RM, Christensen DM, Kanarek DJ, Kiess MC, Boucher CA. Evaluation of bepridil for the treatment of angina pectoris: evidence for preservation of left ventricular function. American Journal of Cardiology 55 (Suppl.C): 30C–35C, 1985

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Lisa M. Hollingshead, Diana Faulds & Andrew Fitton

Authors
  1. Lisa M. Hollingshead
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana Faulds
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew Fitton
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Various sections of the manuscript reviewed by: P. Jaillon, Unité de Pharmacologie Clinique, Hôpital Saint-Antoine, Paris, France; D. Jewitt, Cardiac Department, King’s College Hospital, University of London, London, England; A. Millaire, Hôpital Cardiologique, Centre Hospitalier Régional et Universitaire de Lille, Lille, France; K.A. Narahara, Division of Cardiology, Harbor-UCLA Medical Center, Torrance, California, USA; F. Nielsen-Kudsk, Institute of Pharmacology, University of Aarhus, Aarhus, Denmark; A.P. Rae, Department of Medical Cardiology, Royal Infirmary, Glasgow, Scotland; C. Schmitt, Department of Internal Medicine, University of Heidelberg, Heidelberg, Federal Republic of Germany; B. Surawicz, Department of Medicine, Krannert Institute of Cardiology, Indiana University, Indianapolis, Indiana, USA; M. Thomas, Cardiac Department, King’s College Hospital, University of London, London, England; J. Zaagsma, University Centre for Pharmacy, University of Groningen, Groningen, The Netherlands.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hollingshead, L.M., Faulds, D. & Fitton, A. Bepridil. Drugs 44, 835–857 (1992). https://doi.org/10.2165/00003495-199244050-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199244050-00009

Keywords

Search

Navigation